ArticleCell death & disease2018
The bHLH transcription factor DEC1 promotes thyroid cancer aggressiveness by the interplay with NOTCH1.
Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Inhibition of TGF-β1/Smad signaling reverses the dedifferentiated phenotype of thyroid cancer cells in three-dimensional culture.Journal of endocrinological investigation · 2026Article
- Two Cohorts, One Network: Consensus Master Regulators Orchestrating Papillary Thyroid Carcinoma.International journal of molecular sciences · 2025Article
- DEC1 promotes breast cancer bone metastasis through transcriptional activation of CXCR4.Journal of biomedical research · 2025Article
- Investigating the circadian rhythm signaling pathway in HTLV-1 pathogenesis using Boolean analysis.Virus research · 2025Article
- Developmental basis of natural tooth shape variation in cichlid fishes.Die Naturwissenschaften · 2025Article
- Multimodal ultrasound: a non-invasive method for identifying dedifferentiation of papillary thyroid carcinoma during active surveillance.Frontiers in oncology · 2025Article
- Circadian rhythm disruption and endocrine-related tumors.World journal of clinical oncology · 2024Review
- Biologically informed NeuralODEs for genome-wide regulatory dynamics.Genome biology · 2024Article
- Identification of ECM and EMT relevant genes involved in the progression of bladder cancer through bioinformatics analysis.American journal of clinical and experimental urology · 2024Article
- Hypoxia Induces Alterations in the Circadian Rhythm in Patients with Chronic Respiratory Diseases.Cells · 2023Review
- Relationship between TSH and free thyroxine in outpatient cancer patient population.Endocrine · 2023Article
- A Review of Evidence for the Involvement of the Circadian Clock Genes into Malignant Transformation of Thyroid Tissue.Clocks & sleep · 2023Review
- The role of Hedgehog and Notch signaling pathway in cancer.Molecular biomedicine · 2022Review
- DEC1 promotes progression of Helicobacter pylori-positive gastric cancer by regulating Akt/NF-κB pathway.Journal of cellular and molecular medicine · 2022Article
- Notch signaling pathway: architecture, disease, and therapeutics.Signal transduction and targeted therapy · 2022Review
- Reciprocal Expression of Differentiated Embryonic Chondrocyte Expressed Genes Result in Functional Antagonism in Gastric Cancer.Digestive diseases and sciences · 2022Article
- Article
- Whole-exome sequencing and bioinformatic analyses revealed differences in gene mutation profiles in papillary thyroid cancer patients with and without benign thyroid goitre background.Frontiers in endocrinology · 2022Article
- Mnt Represses Epithelial Identity To Promote Epithelial-to-Mesenchymal Transition.Molecular and cellular biology · 2021Article
- Differentiated embryonic chondrocyte-expressed gene 1 promotes temozolomide resistance by modulating the SP1-MGMT axis in glioblastoma.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant re-activation of transcription factors occurs frequently in cancer. Recently, we found the basic helix-loop-helix transcription factors DEC1 and DEC2 significantly up-regulated in a model of highly aggressive thyroid cancer, raising the hypothesis that these factors might be part of the program driving progression of these tumors. Here, we investigated for the first time the function of DEC1 and DEC2 in thyroid cancer. Using both gain- and loss-of-function approaches, we showed that DEC1 more than DEC2 sustains progression of thyroid cancer by promoting cell growth and invasiveness. We demonstrated that DEC1 controls NOTCH1 expression and that the interplay with the NOTCH pathway is relevant for DEC1 function in thyroid cancer. We confirmed this observation in vivo showing that DEC1 expression is a specific feature of tumor cells, that this transcription factor is significantly over-expressed in all major thyroid cancer histotypes and that its expression correlated with NOTCH1 in these tumors. Finally, we performed RNA-sequencing to define the DEC1-associated gene expression profile in thyroid cancer cells and we discovered that DEC1 drives the expression of many cell cycle-related genes, uncovering a potential new function for this transcription factor in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.